Hence, TCR engineering strategies could provide a more effective means to manipulating T‐cell immunity to target tumour cell elimination.95 The expression of NY‐ESO‐1 and PRAME could be induced by 5‐Aza‐dC treatment in chondrosarcoma cell lines, including in cell lines with absent or almost undetectable expression.96 These findings indicate that with adoptive immunotherapy following 5‐Aza‐dC treatment, NY‐ESO‐1/LAGE‐1s and PRAME‐specific CD8+ effector T cells can treat chondrosarcoma, which might be a promising way to treat patients with unresectable or metastatic chondrosarcoma.96 The gene discussed is CD8A; the disease is chondrosarcoma.